Physician profile
Rachel Sweeney
NPI 1427177146
$2,926.70
in general payments reported to CMS, 2019-2025
17 companies · $393 in 2025
The $393 reported for 2025 was more than what 80% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $481 · 2021: $379 · 2022: $305 · 2023: $322 · 2024: $523 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023 · Entertainment: $197 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.62 |
| Entertainment | $197.40 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $790.17 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $337.97 | 2019-2021 | |
| Alcon Vision LLC | $325.99 | 2021-2024 | Total30, Precision 1 |
| Optos, INC. | $321.99 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $235.44 | 2022-2025 | Miebo, Infuse, Xiidra |
| Visioneering Technologies, INC. | $143.86 | 2024 | |
| Maculogix, INC. | $127.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.29 | 2020 | |
| Sanofi-Aventis U.S. LLC | $102.61 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $85.00 | 2019 | |
| Topcon Healthcare, INC. | $81.41 | 2023 | |
| Harrow Eye, LLC | $75.53 | 2025 | Vevye |
| Dompe US, INC. | $52.45 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $45.93 | 2023-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $36.46 | 2024-2025 | Xdemvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $32.67 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $20.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.